Research programme: cancer therapeutics - Tarveda Therapeutics

Drug Profile

Research programme: cancer therapeutics - Tarveda Therapeutics

Alternative Names: Pentarins™

Latest Information Update: 15 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Blend Therapeutics
  • Developer Tarveda Therapeutics
  • Class Antineoplastons
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors; Somatostatin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neuroendocrine tumours; Small cell lung cancer; Solid tumours

Most Recent Events

  • 27 Jan 2016 Blend Therapeutics is now called Tarveda Therapeutics
  • 07 Jan 2015 Blend Therapeutics in-licenses a ligand technology from an undisclosed Biotechnology company
  • 07 Jan 2015 Preclinical trials in Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top